| Literature DB >> 30964988 |
Robert M Owen, David Blakemore, Lishuang Cao, Neil Flanagan, Rebecca Fish, Karl R Gibson1, Rachel Gurrell, Chan Woo Huh2, Juha Kammonen, Elisabeth Mortimer-Cassen, Sarah A Nickolls, Kiyoyuki Omoto, Dafydd Owen2, Andy Pike, David C Pryde, David S Reynolds, Rosemarie Roeloffs3, Colin Rose2, Clara Stead, Mifune Takeuchi1, Joseph S Warmus2, Christine Watson1.
Abstract
The design, optimization, and evaluation of a series of novel imidazopyridazine-based subtype-selective positive allosteric modulators (PAMs) for the GABAA ligand-gated ion channel are described. From a set of initial hits multiple subseries were designed and evaluated based on binding affinity and functional activity. As designing in the desired level of functional selectivity proved difficult, a probability-based assessment was performed to focus the project's efforts on a single subseries that had the greatest odds of delivering the target profile. These efforts ultimately led to the identification of two precandidates from this subseries, which were advanced to preclinical safety studies and subsequently to the identification of the clinical candidate PF-06372865.Entities:
Mesh：
Substances：
Year: 2019 PMID： 30964988 DOI： 10.1021/acs.jmedchem.9b00322
Source DB: PubMed Journal: J Med Chem ISSN： 0022-2623 Impact factor: 7.446